134
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Idelalisib in indolent NHL – has it finally found its niche?

&
Pages 1029-1030 | Received 30 Sep 2020, Accepted 07 Oct 2020, Published online: 19 Oct 2020
 

Disclosure statement

A.S. has no potential conflict of interest. M.S.D. reports institutional research funding from Ascentage Pharma, Astra-Zeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem, as well as personal fees from AbbVie, Adaptive BioSciences, Ascentage Pharma, Astra-Zeneca, BeiGene, Celgene, Eli Lilly, Genentech, Gilead Sciences, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, and Zentalis.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.